Japan Chemical Daily

Japan's leading chemical industry newspaper

Log In

Nippon Shinyaku Targets 2019 Approval for New Muscular Dystrophy Treatment

Filed Under: Industry, Pharma Tagged With: , , , ,

Nippon Shinyaku Co. Ltd. (TYO:4516) has completed Phase 2 clinical trials in the U.S. for NS-065 as of this February…....

Please subscribe to read the full story.

Subscribe Free Trial

Related Articles:

Coronavirus Report – Part 77: Japan’s Pharmaceutical Companies Move in Quick Order to Treat Infection
Coronavirus Report – Part 77: Japan’s Pharmaceutical…
Coronavirus Report – Part 58: Clinical Trials Begin for Slew of Potential Vaccines
Coronavirus Report – Part 58: Clinical Trials Begin for Slew…
Asahi Kasei Works on New iPS Treatments for Orthopedic Sector
Asahi Kasei Works on New iPS Treatments for Orthopedic…
Spate of Japanese-Developed COVID-19 Vaccines Head Into Later Stages of Development, Clinical Trials
Spate of Japanese-Developed COVID-19 Vaccines Head Into…
Coronavirus Report – Part 67: Pandemic Causes 75% Drop in Clinical Trials for Early April
Coronavirus Report – Part 67: Pandemic Causes 75% Drop in…
Coronavirus Report – Part 27: Pandemic Sees Clinical Trials for New Drugs Suspended, Postponed
Coronavirus Report – Part 27: Pandemic Sees Clinical Trials…